Reply from authors re: Behfar ehdaie, shahrokh F. shariat. magnetic resonance imaging-targeted prostate biopsy: Back to the future. Eur urol 2013;63:141-2: What will it cost to target clinically relevant prostate cancer?

Caroline M. Moore; Nicola L. Robertson; Nasr Arsanious; Thomas Middleton; Arnauld Villers; Laurence Klotz; Samir S. Taneja; Mark Emberton

doi:10.1016/j.eururo.2012.07.036

Reply from authors re: Behfar ehdaie, shahrokh F. shariat. magnetic resonance imaging-targeted prostate biopsy: Back to the future. Eur urol 2013;63:141-2: What will it cost to target clinically relevant prostate cancer?

Caroline M. Moore, Nicola L. Robertson, Nasr Arsanious, Thomas Middleton, Arnauld Villers, Laurence Klotz, Samir S. Taneja, Mark Emberton

Biomedical Engineering

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	143-144
Number of pages	2
Journal	European Urology
Volume	63
Issue number	1
DOIs	https://doi.org/10.1016/j.eururo.2012.07.036
State	Published - Jan 2013

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2012.07.036

Cite this

Moore, C. M., Robertson, N. L., Arsanious, N., Middleton, T., Villers, A., Klotz, L., Taneja, S. S., & Emberton, M. (2013). Reply from authors re: Behfar ehdaie, shahrokh F. shariat. magnetic resonance imaging-targeted prostate biopsy: Back to the future. Eur urol 2013;63:141-2: What will it cost to target clinically relevant prostate cancer? European Urology, 63(1), 143-144. https://doi.org/10.1016/j.eururo.2012.07.036

Reply from authors re: Behfar ehdaie, shahrokh F. shariat. magnetic resonance imaging-targeted prostate biopsy: Back to the future. Eur urol 2013;63:141-2: What will it cost to target clinically relevant prostate cancer? / Moore, Caroline M.; Robertson, Nicola L.; Arsanious, Nasr et al.
In: European Urology, Vol. 63, No. 1, 01.2013, p. 143-144.

Research output: Contribution to journal › Editorial › peer-review

Moore, CM, Robertson, NL, Arsanious, N, Middleton, T, Villers, A, Klotz, L, Taneja, SS & Emberton, M 2013, 'Reply from authors re: Behfar ehdaie, shahrokh F. shariat. magnetic resonance imaging-targeted prostate biopsy: Back to the future. Eur urol 2013;63:141-2: What will it cost to target clinically relevant prostate cancer?', European Urology, vol. 63, no. 1, pp. 143-144. https://doi.org/10.1016/j.eururo.2012.07.036

Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L et al. Reply from authors re: Behfar ehdaie, shahrokh F. shariat. magnetic resonance imaging-targeted prostate biopsy: Back to the future. Eur urol 2013;63:141-2: What will it cost to target clinically relevant prostate cancer? European Urology. 2013 Jan;63(1):143-144. doi: 10.1016/j.eururo.2012.07.036

@article{fbfcdeca615441ec9201c214e86511a6,

title = "Reply from authors re: Behfar ehdaie, shahrokh F. shariat. magnetic resonance imaging-targeted prostate biopsy: Back to the future. Eur urol 2013;63:141-2: What will it cost to target clinically relevant prostate cancer?",

author = "Moore, {Caroline M.} and Robertson, {Nicola L.} and Nasr Arsanious and Thomas Middleton and Arnauld Villers and Laurence Klotz and Taneja, {Samir S.} and Mark Emberton",

note = "Funding Information: Mark Emberton receives research support from the UK National Institute of Health Research University College London Hospitals/University College London Comprehensive Biomedical Research Centre; receives funding from US HIFU, GlaxoSmithKline, and Advanced Medical Diagnostics for clinical trials; is a paid consultant to Steba Biotech; and has received funding from Focused Surgery Inc, Misonix Inc, Oncura (part of GE Healthcare) for medical consultancy and travel to conferences. Caroline M. Moore is a paid consultant to Steba Biotech; has received support for conference attendance from Sanofi, Steba Biotech, Pfizer, and Ipsen; is a proctor for Prostate Mapping; and receives research support from GlaxoSmithKline and Advanced Medical Diagnostics. Samir S. Taneja is a consultant for Eigen Corporation, a consultant and scientific investigator for GTx Biotech, a scientific investigator for Steba Biotech, a speaker for Janssen, an editor for and recipient of book royalties from Elsevier, and a scientific investigator for the US National Institutes of Health (NIH) National Cancer Institute and receives scientific support/funding from the NIH, the US Department of Defence, and the Joseph and Diane Charitable Trust. The other authors have nothing to disclose.",

year = "2013",

month = jan,

doi = "10.1016/j.eururo.2012.07.036",

language = "English (US)",

volume = "63",

pages = "143--144",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Reply from authors re

T2 - Behfar ehdaie, shahrokh F. shariat. magnetic resonance imaging-targeted prostate biopsy: Back to the future. Eur urol 2013;63:141-2: What will it cost to target clinically relevant prostate cancer?

AU - Moore, Caroline M.

AU - Robertson, Nicola L.

AU - Arsanious, Nasr

AU - Middleton, Thomas

AU - Villers, Arnauld

AU - Klotz, Laurence

AU - Taneja, Samir S.

AU - Emberton, Mark

N1 - Funding Information: Mark Emberton receives research support from the UK National Institute of Health Research University College London Hospitals/University College London Comprehensive Biomedical Research Centre; receives funding from US HIFU, GlaxoSmithKline, and Advanced Medical Diagnostics for clinical trials; is a paid consultant to Steba Biotech; and has received funding from Focused Surgery Inc, Misonix Inc, Oncura (part of GE Healthcare) for medical consultancy and travel to conferences. Caroline M. Moore is a paid consultant to Steba Biotech; has received support for conference attendance from Sanofi, Steba Biotech, Pfizer, and Ipsen; is a proctor for Prostate Mapping; and receives research support from GlaxoSmithKline and Advanced Medical Diagnostics. Samir S. Taneja is a consultant for Eigen Corporation, a consultant and scientific investigator for GTx Biotech, a scientific investigator for Steba Biotech, a speaker for Janssen, an editor for and recipient of book royalties from Elsevier, and a scientific investigator for the US National Institutes of Health (NIH) National Cancer Institute and receives scientific support/funding from the NIH, the US Department of Defence, and the Joseph and Diane Charitable Trust. The other authors have nothing to disclose.

PY - 2013/1

Y1 - 2013/1

UR - http://www.scopus.com/inward/record.url?scp=84870546696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870546696&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2012.07.036

DO - 10.1016/j.eururo.2012.07.036

M3 - Editorial

AN - SCOPUS:84870546696

SN - 0302-2838

VL - 63

SP - 143

EP - 144

JO - European Urology

JF - European Urology

IS - 1

ER -

Reply from authors re: Behfar ehdaie, shahrokh F. shariat. magnetic resonance imaging-targeted prostate biopsy: Back to the future. Eur urol 2013;63:141-2: What will it cost to target clinically relevant prostate cancer?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this